Adipogen/BAY 43-9006/AG-CR1-0025-M025/25 mg-蚂蚁淘生物

More Information Product Details Synonyms Product Type Properties Formula MW CAS Purity Chemicals Appearance Solubility Identity InChi Key Shipping and Handling Shipping Short Term Storage Long Term Storage Use/Stability Documents MSDS Product Specification Sheet Datasheet

Sorafenib; N-[4-Chloro-3-(trifluoromethyl)phenyl]-([4-[2-(N-methylcarbamoyl)(4-pyridyloxy)]phenyl]amino)-carboxamide

Chemical

C₂₁H₁₆ClF₃N₄O₃

464.8

284461-73-0

≥98% (NMR)

White to off-white solid.

Soluble in DMSO, 100% ethanol, methanol or ethyl acetate.

Determined by ¹H-NMR.

MLDQJTXFUGDVEO-UHFFFAOYSA-N

AMBIENT

+4°C

-20°C

Stable for at least 2 years after receipt when stored at -20°C.

Download PDF

Antitumor compound [1].
Broad-spectrum kinase inhibitor [2].
Raf kinase inhibitor [2, 3].
Apoptosis inducer [3, 4].
Cytostatic [5].
Angiogenesis inhibitor [2, 5].
Review [6].

Product References

BAY 43-9006: preclinical data: S. Wilhelm & D.S. Chien; Curr. Pharm. Des. 8, 2255 (2002)

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature: L. Adnane, et al.; Meth. Enzymol. 407, 597 (2005)

The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells: D.J. Panka, et al.; Cancer Res. 66, 1611 (2006)

The kinase inhibitor Sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress: M. Rahmani, et al.; Mol. Cell. Biol. 27, 5499 (2007)

BAY-43-9006 Bayer/Onyx: J.T. Lee & J.A. McCubrey; Curr. Opin. Investig. Drugs 4, 757 (2003)

Sorafenib (BAY 43-9006): review of clinical development: R. Ng & E.X. Chen; Curr. Clin. Pharmacol. 1, 223 (2006)

友情链接